ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms of Sjögren's Syndrome, 4th Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 1328

Special Issue Editor


E-Mail Website
Guest Editor
Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
Interests: systemic lupus erythematosus; sjögren’s syndrome; prolidase deficiency; free radical biology; experimental urolithiasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Sjögren’s syndrome (SS) is a systemic autoimmune rheumatic disorder characterized by B-cells’ infiltration of exocrine glands and the production of autoantibodies to self-antigens, such as Ro60 (SS-A), La (SS-B), and muscarinic 3 receptors. The most common symptoms of SS are dry eyes (keratoconjunctivitis sicca), dry mouth (xerostomia), and extreme tiredness. Additional symptoms include dryness of the skin, nose, throat, and vagina; arthralgias and myalgias; peripheral neuropathies; pulmonary, thyroid, and renal disorders; and lymphoma. Increased levels of tissue and serum cytokines and tissue fibrosis are also seen in patients with SS. Females account for 90% of all SS cases. Two age peaks have been identified for primary SS: the first is after menarche (twenties to thirties), and the second is after menopause (mid-fifties). SS can occur alone (primary SS) or along with another autoimmune diseases (secondary SS), such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune hypothyroidism, and systemic sclerosis. The molecular mechanisms mediating pathological dysfunction in SS remain to be elucidated despite there being extensive studies investigating the underlying cause of Sjögren’s syndrome. There is currently no cure for Sjögren's syndrome, and treatment is mainly palliative.

In this Special Issue of IJMS, we seek articles that can better explain the molecular mechanisms mediating the pathological conditions of Sjögren’s syndrome. We welcome articles that provide insights into the molecular aspects of the initiation and progression of the disease by glandular vascular endothelial cells, environmental triggers, free radical-mediated oxidative damage, the cytokine activation of lymphocytes, glandular lymphocyte and dendritic cell homing, the structure and function of autoantigens and autoantibody induction, germinal center-like structure formation, and the apoptosis of glandular cells. We also welcome review papers in these areas and articles describing novel therapeutic targets and treatment options, new diagnostic tools, and biomarkers.

Dr. Biji Theyilamannil Kurien
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmunity
  • sjögren’s syndrome
  • autoantibodies
  • salivary gland
  • lacrimal gland
  • dry eyes/mouth

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1552 KB  
Article
Evaluating Anti-CCL25 as a Therapeutic Strategy to Disrupt Foci Formation in a Spontaneous Murine Model of Sjögren’s Disease
by Martha Tsaliki, Biji T. Kurien, Joshua Cavett, John A. Ice, Kristi A. Koelsch and Robert Hal Scofield
Int. J. Mol. Sci. 2025, 26(18), 8802; https://doi.org/10.3390/ijms26188802 - 10 Sep 2025
Viewed by 327
Abstract
Sjögren’s disease (SjD) targets the salivary and lacrimal glands and is characterized by autoantibody production and glandular lymphocytic infiltrate with ectopic germinal centers (EGCs). The chemokine CCL25 recruits CCR9+ CD4+ T cells to the salivary glands to promote B cell activation. [...] Read more.
Sjögren’s disease (SjD) targets the salivary and lacrimal glands and is characterized by autoantibody production and glandular lymphocytic infiltrate with ectopic germinal centers (EGCs). The chemokine CCL25 recruits CCR9+ CD4+ T cells to the salivary glands to promote B cell activation. However, the therapeutic potential of targeting the CCL25–CCR9 axis to limit glandular inflammation and lymphoid neogenesis remains largely unexplored. Evaluate whether blocking the CCL25–CCR9+ T cell axis with a monoclonal antibody could reduce immune infiltration, ectopic germinal center (EGC) formation, and local autoantibody production in the NOD.H2(h4) mouse model of SjD. Female NOD.H2(h4) mice were administered anti-CCL25 antibody, isotype control, or PBS intraperitoneally for 12 weeks. Sera and saliva were collected to evaluate anti-Ro52 antibodies via ELISA across treatment groups. Salivary glands were harvested and processed for H&E staining to assess lymphocytic infiltration and focus scores. Treatment with α-CCL25 was well tolerated, with no significant differences in body weight or stimulated salivary flow between treatment groups. Histopathological evaluation revealed no reduction in lymphocytic infiltration, focus scores, or percentage of inflamed tissue in α-CCL25-treated mice compared to controls. Anti-Ro52 antibodies were undetectable in plasma or saliva across all groups and timepoints. Systemic CCL25 blockade did not significantly alter salivary gland inflammation, function, or autoantibody production in NOD.H2(h4) mice. These findings suggest that monotherapy targeting the CCL25–CCR9 axis may be insufficient to resolve glandular autoimmunity in this model and that additional or combinatorial strategies may be necessary for effective intervention. Full article
(This article belongs to the Special Issue Molecular Mechanisms of Sjögren's Syndrome, 4th Edition)
Show Figures

Figure 1

Back to TopTop